(Reuters) -Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...

Novo Nordisk (NVO) announced updates to the Wegovy savings program, allowing all eligible cash-paying patients access to Wegovy injection 0.25 ...

Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...

PLAINSBORO, N.J., March 24, 2025 /PRNewswire/ -- Today, Novo Nordisk announced updates to the Wegovy ® savings program, allowing all eligible cash-paying patients access to Wegovy ® (semaglutide ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Novo Nordisk, which manufactures the fiercely popular weight-loss drug Wegovy, previously forecast weight loss of 25% for patients who take CagriSema. In another late-trial result published in ...

March 24 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a discounted price of $499 ...

It subsequently sold three Catalent manufacturing plants to Novo Nordisk for $11 billion to boost Wegovy production. However, total assets under management dropped slightly to 142 billion euros in ...